My wife is triple negative breast cancer patient. After several rounds of treatments and 3 different clinical trials, we are trying to figure out which trial to choose.
IMMU-132 is antibody drug conjugate: 3 out of 4 patients of TNBC had good response (6 months, 10 months, 3 months, 1 did not survive): Phase II
MEDI4736: immunotherapy, has been good in small cell lung cancer. But my wife is TNBC and this trial is single agent. We have not found out any data on this drug for TNBC.
need help to prioritize one over the other?
Background: 35 yr old, Stage IV, cancer in skin only.
treatments: taxol, FAC, bilateral mastectomy, radiation, ixempra+xeloda, chest wall surgery
trials: olaparib+BKM120, veliparib+ironitican, MEK+AKT2 inhibitor